Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer
- 1 November 2011
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 74 (2) , 318-325
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Lung Cancer Among Postmenopausal Women Treated With Estrogen Alone in the Women's Health Initiative Randomized TrialJNCI: Journal of the National Cancer Institute, 2010
- Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trialThe Lancet, 2009
- Estrogen receptor beta (ERβ) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cellsThe Journal of Steroid Biochemistry and Molecular Biology, 2009
- Novel actions of estrogen to promote proliferation: Integration of cytoplasmic and nuclear pathwaysSteroids, 2009
- Targeting Aromatase and Estrogen Signaling in Human Non‐Small Cell Lung CancerAnnals of the New York Academy of Sciences, 2009
- Lung dysfunction causes systemic hypoxia in estrogen receptor β knockout (ERβ −/− ) miceProceedings of the National Academy of Sciences, 2006
- Estrogen Carcinogenesis in Breast CancerNew England Journal of Medicine, 2006
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998